Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders
Carlos M. Martínez‐Viturro, Andrés A. Trabanco, Jordi Royes, Elena Fernández, Gary Tresadern, Juan A. Vega, Alcira del Cerro, Francisca Delgado, Aránzazu García Molina, Fulgencio Tovar, P.L. Shaffer, Andreas Ebneth, Alexis Bretteville, Liesbeth Mertens, Marijke Somers, José M. Alonso, José Manuel Bartolomé-Nebreda
Abstract
O-GlcNAcylation is a post-translational modification of tau understood to lower the speed and yield of its aggregation, a pathological hallmark of Alzheimer’s disease (AD). O-GlcNAcase (OGA) is the only enzyme that removes O-linked N-acetyl-d-glucosamine (O-GlcNAc) from target proteins. Therefore, inhibition of OGA represents a potential approach for the treatment of AD by preserving the O-GlcNAcylated tau protein. Herein, we report the multifactorial optimization of high-throughput screening hit 8 to a potent, metabolically stable, and orally bioavailable diazaspirononane OGA inhibitor (+)-56. The human OGA X-ray crystal structure has been recently solved, but bacterial hydrolases are still widely used as structural homologues. For the first time, we reveal how a nonsaccharide series of inhibitors binds bacterial OGA and discuss the suitability of two different bacterial orthologues as surrogates for human OGA. These breakthroughs enabled structure–activity relationships to be understood and provided context and boundaries for the optimization of druglike properties.